Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737935 | 0.92 | RAPGEF3 (0.44) | RAPGEF3POLBSMN1; SMN2CHRM1HTR2A | |
| SCHEMBL6734536 | 0.85 | SMN1; SMN2 (0.48) | RAPGEF3ALDH1A1TSHRPOLBMAPT | |
| SCHEMBL6734631 | 0.80 | RAPGEF3 (0.38) | RAPGEF3SMN1; SMN2MCHR1HRH3 | |
| SCHEMBL6734463 | 0.78 | ACKR3 (0.44) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6733733 | 0.76 | RAPGEF3 (0.39) | RAPGEF3POLBSMN1; SMN2MCHR1HRH3 | |
| SCHEMBL6729982 | 0.75 | HRH3 (0.40) | RAPGEF3MCHR1HRH3 | |
| SCHEMBL7659514 | 0.75 | RAPGEF3 (0.46) | RAPGEF3MCHR1HRH3 | |
| SCHEMBL7660195 | 0.74 | HRH3 (0.47) | RAPGEF3ALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL6733915 | 0.73 | HRH3 (0.40) | RAPGEF3POLBMAPTMEN1KMT2A | |
| SCHEMBL6805174 | 0.71 | HRH3 (0.40) | RAPGEF3MCHR1HRH3CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885ALDH1A1 569/4885TSHR 2768/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885ALDH1A1 569/4885TSHR 2768/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | RAPGEF3 2984/4885ALDH1A1 569/4885TSHR 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.